Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Freiburg Im Breisgau – page 15

529 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freiburg Im Breisgau at a glance
529
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

529 trials in Freiburg Im Breisgau

Open in trial search

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Invasive lobular breast carcinoma

Recruiting

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Pulmonary sarcoidosis

Recruiting

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Metastases to meninges

Recruiting

Study of Nivolumab for Patients with Metastatic Solid Tumors and Leptomeningeal Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Glioblastoma

Recruiting

Study of Meclofenamate Sodium and Temozolomide for Patients with Progressive MGMT-Methylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Meclofenamate Sodium
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Peritonitis+2

Recruiting

Study on the Effects of Immunoglobulin A, G, and M in Patients with Peritonitis and Sepsis After Infection Control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Immunoglobulin A
  • Sponsor:Universitaetsklinikum Aachen AöR

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Hepatic cirrhosis

Recruiting

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer, non-small cell lung cancer, and colon cancer treatments. Studies evaluating new therapeutic approaches for both early-stage and advanced cancers.

  • Breast Cancer Therapy Optimization
  • Advanced Lung Cancer Treatments
  • Gastrointestinal Cancer Research

Emphasis on targeted therapies and combination treatments to improve patient outcomes.

02 Autoimmune Conditions

Research into treatments for psoriatic arthritis, rheumatoid arthritis, and Sjögren's disease. Studies evaluating novel biologics and targeted therapies.

  • Inflammatory Arthritis Management
  • Autoimmune Disease Therapeutics
  • Novel Treatment Approaches

Focus on improving disease control and quality of life for patients with chronic autoimmune conditions.

03 Rare Diseases

Clinical investigations of treatments for spinal muscular atrophy, sickle cell disease, and primary sclerosing cholangitis. Studies aimed at developing innovative therapies.

  • Genetic Disease Treatments
  • Blood Disorders
  • Pediatric Rare Diseases

Dedicated to finding breakthrough treatments for challenging rare conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.